Drug Profile


Alternative Names: 311-C90; 311C; AscoTop; BW-311C90; Zomig; Zomig-ZMT; Zomigon

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Burroughs Wellcome
  • Developer AstraZeneca; Impax Pharmaceuticals
  • Class Antimigraines; Oxazolidinones; Small molecules; Tryptamines
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cluster headache; Menstrual migraine; Migraine

Most Recent Events

  • 07 Jun 2017 Zolmitriptan licensed to Grunenthal worldwide (excluding Japan) for the treatment of migraines and cluster headaches
  • 30 Mar 2017 US District Court, District of Delaware, rules that the US patents protecting zolmitriptan Nasal Spray were not invalid and were infringed by the Lannett Holdings
  • 16 Jun 2015 Launched for Migraine (In adolescents) in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top